• eTheRNA
  • Follow our progress in developing products that have the potential to transform the future of cancer treatment

eTheRNA immunotherapies CEO to present at Bio Europe 2017

Niel (Belgium), 1 November 2017 — eTheRNA Immunotherapies, a clinical-stage company developing mRNA-based cancer immunotherapies based on its unique TriMix platform, announces that CEO Dirk Reyn is to present at Bio-Europe 2017 in Berlin.

The presentation will take place on Wednesday 8th November at 9:45am in the ‘Cell and gene therapy track’.

This year’s BIO-Europe conference will take place from 6-8 November at CityCube in Berlin, Germany. The conference brings together thousands of attendees from the life sciences industry and offers the greatest opportunity to meet senior licensing executives from global pharma organisations and senior management of innovative drug development and platform technology companies.

eTheRNA immunotherapies awarded €1 million grant from Flanders Innovation & Entrepreneurship to further upgrade its state-of-the-art production process for TriMix mRNA immunotherapies

Niel (Belgium), 25 September 2017 — eTheRNA Immunotherapies, a clinical-stage company developing mRNA-based cancer immunotherapies from its unique TriMix platform, announces it has been awarded a €1 million industrial R&D Projects Grant by Flanders Innovation & Entrepreneurship (VLAIO). The grant will be used by eTheRNA to further develop and optimize its state-of-the-art production process for generating the mRNA components of its TriMix platform, and for clinical trials of innovative and rationally designed mRNA cancer immunotherapies derived from this platform. The improved production process will enable the Company to further reduce its production time and cost of goods and generate more revenues from the production of GMP-grade mRNA for third parties.

The Company’s unique TriMix platform combines three mRNAs encoding proteins that act highly synergistically to activate dendritic cells (DCs), a type of dedicated immune cells also known as antigen presenting cells (APC), to promote enhanced T-cell immunity. In combination with mRNA coding for tumor-specific antigens, TriMix products can also promote an antigen-directed cytotoxic T-cell response.

eTheRNA immunotherapies to present at Sachs Biotech in Europe Forum

Niel (Belgium), 21 September 2017 — eTheRNA immunotherapies, a clinical-stage company developing mRNA-based cancer immunotherapies from its unique TriMix platform, announces that its CEO Dirk Reyn is to present an overview of the company, its novel technologies and development pipeline at the Sachs 17th Biotech in Europe Forum for Global Partnering and Investment.

The presentation will take place on 27 September at 12:15pm in Presentation Track C, which takes place at the Congress Center, Basel, Switzerland.

eTheRNA advances in-vivo mRNA cancer immunotherapy into first oncology clinical studies

TriMix-MEL (ECI-006), a rationally designed mRNA immunotherapy based on the unique TriMix platform, starts Phase Ib trial in adjuvant melanoma patients

Niel (Belgium), 30 June 2017 – eTheRNA immunotherapies, a clinical-stage company developing mRNA based cancer immunotherapies from its unique TriMix platform, announces the start of the first Phase Ib oncology clinical study evaluating its novel candidate TriMix-MEL (ECI-006) in metastatic melanoma patients showing no evidence of disease after surgical removal of their tumor, but at risk for disease recurrence.